18 results on '"Harris, LaTreace Q."'
Search Results
2. Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics -- United States, September 1, 2022-September 30, 2023.
- Author
-
El Kalach, Roua, Jones-Jack, Nkenge, Elam, Mattie A., Olorukooba, Abdulhakeem, Vazquez, Marley, Stokley, Shannon, Meyer, Sarah, McGarvey, Sunanda, Nguyen, Kimvy, Scharf, Lynn Gibbs, Harris, LaTreace Q., Duggar, Christopher, and Moore, Lori B.
- Subjects
COVID-19 vaccines ,SOCIODEMOGRAPHIC factors ,MINORITIES ,PUBLIC health - Abstract
The Federal Retail Pharmacy Program (FRPP) facilitated integration of pharmacies as partners in national efforts to scale up vaccination capacity during the COVID-19 pandemic emergency response. To evaluate FRPP's contribution to vaccination efforts across various sociodemographic groups, data on COVID-19 bivalent mRNA vaccine doses administered during September 1, 2022-September 30, 2023, were evaluated from two sources: 1) FRPP data reported directly to CDC and 2) jurisdictional immunization information systems data reported to CDC from all 50 states, the District of Columbia, U.S. territories, and freely associated states. Among 59.8 million COVID-19 bivalent vaccine doses administered in the United States during this period, 40.5 million (67.7%) were administered by FRPP partners. The proportion of COVID-19 bivalent doses administered by FRPP partners ranged from 5.9% among children aged 6 months-4 years to 70.6% among adults aged 18-49 years. Among some racial and ethnic minority groups (e.g., Hispanic or Latino, non-Hispanic Black or African American, non-Hispanic Native Hawaiian or other Pacific Islander, and non-Hispanic Asian persons), ≥45% of COVID-19 bivalent vaccine doses were administered by FRPP partners. Further, in urban and rural areas, FRPP partners administered 81.6% and 60.0% of bivalent vaccine doses, respectively. The FRPP partnership administered approximately two thirds of all bivalent COVID-19 vaccine doses in the United States and provided vaccine access for persons across a wide range of sociodemographic groups, demonstrating that this program could serve as a model to address vaccination services needs for routine vaccines and to provide health services in other public health emergencies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5-11 Years--United States, November 1, 2021-April 25, 2022
- Author
-
DeCuir, Jennifer, Meng, Lu, Pan, Yi, Vogt, Tara, Chatham-Stevens, Kevin, Meador, Seth, Shaw, Lauren, Black, Carla L., and Harris, LaTreace Q.
- Subjects
Pfizer Inc. ,Biological products industry ,Children's furniture ,Vaccination ,Pharmaceutical industry ,Health - Abstract
COVID-19 can lead to severe outcomes in children, including multisystem inflammatory syndrome, hospitalization, and death (1,2). On November 2, 2021, the Advisory Committee on Immunization Practices issued an interim recommendation [...]
- Published
- 2022
4. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties--United States, December 14, 2020-January 31, 2022
- Author
-
Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Castro-Roman, Patricia, Fast, Hannah, Meng, Lu, Shaw, Lauren, Gibbs-Scharf, Lynn, Chorba, Terence, Harris, LaTreace Q., and Murthy, Neil
- Subjects
Pfizer Inc. ,Vaccination ,Pharmaceutical industry ,Health - Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late [...]
- Published
- 2022
5. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged [greater than or equal to] 65 Years--United States, August 13, 2021-November 19, 2021
- Author
-
Fast, Hannah E., Zell, Elizabeth, Murthy, Bhavini Patel, Murthy, Neil, Meng, Lu, Scharf, Lynn Gibbs, Black, Carla L., Shaw, Lauren, Chorba, Terence, and Harris, LaTreace Q.
- Subjects
United States. Department of Health and Human Services ,Pfizer Inc. ,Vaccination -- Health aspects ,Adults -- Health aspects ,Pharmaceutical industry -- Health aspects ,Health - Abstract
On December 10, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Vaccination against SARS-CoV-2 (the virus that causes COVID-19) is highly effective at [...]
- Published
- 2021
6. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years--United States, December 14, 2020-July 31, 2021
- Author
-
Murthy, Bhavini Patel, Zell, Elizabeth, Saelee, Ryan, Murthy, Neil, Meng, Lu, Meador, Seth, Reed, Kirsten, Shaw, Lauren, Gibbs-Scharf, Lynn, McNaghten, A.D., Patel, Anita, Stokley, Shannon, Flores, Stephen, Yoder, Jonathan S., Black, Carla L., and Harris, LaTreace Q.
- Subjects
United States. Food and Drug Administration -- Reports ,Johnson & Johnson -- Reports ,Pfizer Inc. -- Reports ,Vaccination -- Reports ,Teenagers -- Reports ,Youth -- Reports ,Evidence-based medicine -- Reports ,Pharmaceutical industry -- Reports ,Health - Abstract
On August 27, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Although severe COVID-19 illness and hospitalization are more common among adults, these [...]
- Published
- 2021
7. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties--United States, December 14, 2020-April 10, 2021
- Author
-
Murthy, Bhavini Patel, Sterrett, Natalie, Weller, Daniel, Zell, Elizabeth, Reynolds, Laura, Toblin, Robin L., Murthy, Neil, Kriss, Jennifer, Rose, Charles, Cadwell, Betsy, Wang, Alice, Ritchey, Matthew D., Gibbs-Scharf, Lynn, Qualters, Judith R., Shaw, Lauren, Brookmeyer, Kathryn A., Clayton, Heather, Eke, Paul, Adams, Laura, Zajac, Julie, Patel, Anita, Fox, Kimberley, Williams, Charnetta, Stokley, Shannon, Flores, Stephen, Barbour, Kamil E., and Harris, LaTreace Q.
- Subjects
Johnson & Johnson ,Vaccination ,Medically uninsured persons ,Pharmaceutical industry ,Health - Abstract
On May 18, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Approximately 60 million persons in the United States live in rural counties, [...]
- Published
- 2021
8. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons--United States, December 14, 2020-February 14, 2021
- Author
-
Kriss, Jennifer L., Reynolds, Laura E., Wang, Alice, Stokley, Shannon, Cole, Matthew M., Harris, LaTreace Q., Shaw, Lauren K., Black, Carla L., Singleton, James A., Fitter, David L., Rose, Dale A., Ritchey, Matthew D., and Toblin, Robin L.
- Subjects
Pfizer Inc. ,Vaccination ,Pharmaceutical industry ,Health - Abstract
On March 15, 2021, this report wasposted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) received Emergency Use Authorization [...]
- Published
- 2021
9. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program--United States, December 14, 2020-January 14, 2021
- Author
-
Painter, Elizabeth M., Ussery, Emily N., Patel, Anita, Hughes, Michelle M., Zell, Elizabeth R., Moulia, Danielle L., Scharf, Lynn Gibbs, Lynch, Michael, Ritchey, Matthew D., Toblin, Robin L., Murthy, Bhavini Patel, Harris, LaTreace Q., Wasley, Annemarie, Rose, Dale A., Cohn, Amanda, and Messonnier, Nancy E.
- Subjects
Pfizer Inc. ,Vaccination ,Long-term care of the sick ,Long-term care facilities ,Pharmaceutical industry ,Health - Abstract
On February 1, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) were authorized for [...]
- Published
- 2021
10. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months--4 Years -- United States, June 20--December 31, 2022.
- Author
-
Patel Murthy, Bhavini, Fast, Hannah E., Zell, Elizabeth, Murthy, Neil, Lu Meng, Shaw, Lauren, Vogt, Tara, Chatham-Stephens, Kevin, Santibanez, Tammy A., Gibbs-Scharf, Lynn, and Harris, LaTreace Q.
- Subjects
COVID-19 vaccines ,DISEASES ,IMMUNIZATION ,HOSPITAL care ,POPULATION - Abstract
The article presents the discussion on COVID-19 illness and hospitalization being more common among older adults. Topics include CDC by jurisdictions, pharmacies, and federal entities through immunization information systems (IISs); and tests for statistical significance being notconducted due to the data reflecting the U.S. population not based on population samples.
- Published
- 2023
- Full Text
- View/download PDF
11. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021
- Author
-
Fast, Hannah E., primary, Zell, Elizabeth, additional, Murthy, Bhavini Patel, additional, Murthy, Neil, additional, Meng, Lu, additional, Scharf, Lynn Gibbs, additional, Black, Carla L., additional, Shaw, Lauren, additional, Chorba, Terence, additional, and Harris, LaTreace Q., additional
- Published
- 2021
- Full Text
- View/download PDF
12. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022.
- Author
-
Murthy BP, Fast HE, Zell E, Murthy N, Meng L, Shaw L, Vogt T, Chatham-Stephens K, Santibanez TA, Gibbs-Scharf L, and Harris LQ
- Subjects
- Infant, United States epidemiology, Humans, Child, Adolescent, Aged, Vaccination Coverage, 2019-nCoV Vaccine mRNA-1273, BNT162 Vaccine, Vaccination, District of Columbia, Demography, COVID-19 Vaccines, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Although severe COVID-19 illness and hospitalization are more common among older adults, children can also be affected (1). More than 3 million cases of COVID-19 had been reported among infants and children aged <5 years (children) as of December 2, 2022 (2). One in four children hospitalized with COVID-19 required intensive care; 21.2% of cases of COVID-19-related multisystem inflammatory syndrome in children (MIS-C) occurred among children aged 1-4 years, and 3.2% of MIS-C cases occurred among infants aged <1 year (1,3). On June 17, 2022, the Food and Drug Administration issued an Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine for children aged 6 months-5 years and the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 years. To assess COVID-19 vaccination coverage among children aged 6 months-4 years in the United States, coverage with ≥1 dose* and completion of the 2-dose or 3-dose primary vaccination series
† were assessed using vaccine administration data for the 50 U.S. states and District of Columbia submitted from June 20 (after COVID-19 vaccine was first authorized for this age group) through December 31, 2022. As of December 31, 2022, ≥1-dose COVID-19 vaccination coverage among children aged 6 months-4 years was 10.1% and was 5.1% for series completion. Coverage with ≥1 dose varied by jurisdiction (range = 2.1% [Mississippi] to 36.1% [District of Columbia]) as did coverage with a completed series (range = 0.7% [Mississippi] to 21.4% [District of Columbia]), respectively. By age group, 9.7 % of children aged 6-23 months and 10.2% of children aged 2-4 years received ≥1 dose; 4.5% of children aged 6-23 months and 5.4% of children aged 2-4 years completed the vaccination series. Among children aged 6 months-4 years, ≥1-dose COVID-19 vaccination coverage was lower in rural counties (3.4%) than in urban counties (10.5%). Among children aged 6 months-4 years who received at least the first dose, only 7.0% were non-Hispanic Black or African American (Black), and 19.9% were Hispanic or Latino (Hispanic), although these demographic groups constitute 13.9% and 25.9% of the population, respectively (4). COVID-19 vaccination coverage among children aged 6 months-4 years is substantially lower than that among older children (5). Efforts are needed to improve vaccination coverage among children aged 6 months-4 years to reduce COVID-19-associated morbidity and mortality., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2023
- Full Text
- View/download PDF
13. COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5-11 Years - United States, November 1, 2021-April 25, 2022.
- Author
-
DeCuir J, Meng L, Pan Y, Vogt T, Chatham-Stevens K, Meador S, Shaw L, Black CL, and Harris LQ
- Subjects
- Ambulatory Care Facilities, BNT162 Vaccine, COVID-19 Vaccines, Child, Humans, Systemic Inflammatory Response Syndrome, United States epidemiology, Vaccination, Vaccination Coverage, COVID-19 complications, COVID-19 epidemiology, COVID-19 prevention & control, Vaccines
- Abstract
COVID-19 can lead to severe outcomes in children, including multisystem inflammatory syndrome, hospitalization, and death (1,2). On November 2, 2021, the Advisory Committee on Immunization Practices issued an interim recommendation for use of the BNT162b2 (Pfizer-BioNTech) vaccine in children aged 5-11 years for the prevention of COVID-19; however, vaccination coverage in this age group remains low (3). As of June 7, 2022, 36.0% of children aged 5-11 years in the United States had received ≥1 of COVID-19 vaccine (3). Among factors that might influence vaccination coverage is the availability of vaccine providers (4). To better understand how provider availability has affected COVID-19 vaccination coverage among children aged 5-11 years, CDC analyzed data on active COVID-19 vaccine providers and county-level vaccine administration data during November 1, 2021-April 25, 2022. Among 2,586 U.S. counties included in the analysis, 87.5% had at least one active COVID-19 vaccine provider serving children aged 5-11 years. Among the five assessed active provider types, most counties had at least one pharmacy (69.1%) or public health clinic (61.3%), whereas fewer counties had at least one pediatric clinic (29.7%), family medicine clinic (29.0%), or federally qualified health center (FQHC)* (22.8%). Median county-level vaccination coverage was 14.5% (IQR = 8.9%-23.6%). After adjusting for social vulnerability index (SVI)
† and urbanicity, the analysis found that vaccination coverage among children aged 5-11 years was higher in counties with at least one active COVID-19 vaccine provider than in counties with no active providers (adjusted rate ratio [aRR] = 1.66). For each provider type, presence of at least one provider in the county was associated with higher coverage; the largest difference in vaccination coverage was observed between counties with and without pediatric clinics (aRR = 1.37). Ensuring broad access to COVID-19 vaccines, in addition to other strategies to address vaccination barriers, could help increase vaccination coverage among children aged 5-11 years., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2022
- Full Text
- View/download PDF
14. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022.
- Author
-
Saelee R, Zell E, Murthy BP, Castro-Roman P, Fast H, Meng L, Shaw L, Gibbs-Scharf L, Chorba T, Harris LQ, and Murthy N
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Rural Population, United States epidemiology, Urban Population, COVID-19 Vaccines administration & dosage, Healthcare Disparities, Vaccination Coverage
- Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late 2021 and early 2022 (1,2). Rural populations tend to be older (aged ≥65 years) and uninsured and are more likely to have underlying medical conditions and live farther from facilities that provide tertiary medical care, placing them at higher risk for adverse COVID-19 outcomes (2). To better understand COVID-19 vaccination disparities between urban and rural populations, CDC analyzed county-level vaccine administration data among persons aged ≥5 years who received their first dose of either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccine or a single dose of the Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine during December 14, 2020-January 31, 2022, in 50 states and the District of Columbia (DC). COVID-19 vaccination coverage with ≥1 doses in rural areas (58.5%) was lower than that in urban counties (75.4%) overall, with similar patterns across age groups and sex. Coverage with ≥1 doses varied among states: 46 states had higher coverage in urban than in rural counties, one had higher coverage in rural than in urban counties. Three states and DC had no rural counties; thus, urban-rural differences could not be assessed. COVID-19 vaccine primary series completion was higher in urban than in rural counties. However, receipt of booster or additional doses among primary series recipients was similarly low between urban and rural counties. Compared with estimates from a previous study of vaccine coverage among adults aged ≥18 years during December 14, 2020-April 10, 2021, these urban-rural disparities among those now eligible for vaccination (aged ≥5 years) have increased more than twofold through January 2022, despite increased availability and access to COVID-19 vaccines. Addressing barriers to vaccination in rural areas is critical to achieving vaccine equity, reducing disparities, and decreasing COVID-19-related illness and death in the United States (2)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2022
- Full Text
- View/download PDF
15. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021.
- Author
-
Murthy BP, Zell E, Saelee R, Murthy N, Meng L, Meador S, Reed K, Shaw L, Gibbs-Scharf L, McNaghten AD, Patel A, Stokley S, Flores S, Yoder JS, Black CL, and Harris LQ
- Subjects
- Adolescent, COVID-19 epidemiology, Child, Female, Humans, Male, United States epidemiology, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Vaccination Coverage statistics & numerical data
- Abstract
Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with COVID-19 during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series
† among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19-associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2021
- Full Text
- View/download PDF
16. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021.
- Author
-
Murthy BP, Sterrett N, Weller D, Zell E, Reynolds L, Toblin RL, Murthy N, Kriss J, Rose C, Cadwell B, Wang A, Ritchey MD, Gibbs-Scharf L, Qualters JR, Shaw L, Brookmeyer KA, Clayton H, Eke P, Adams L, Zajac J, Patel A, Fox K, Williams C, Stokley S, Flores S, Barbour KE, and Harris LQ
- Subjects
- Adolescent, Adult, Aged, COVID-19 epidemiology, COVID-19 prevention & control, Female, Humans, Male, Middle Aged, United States epidemiology, Young Adult, COVID-19 Vaccines administration & dosage, Healthcare Disparities statistics & numerical data, Rural Population statistics & numerical data, Urban Population statistics & numerical data, Vaccination Coverage statistics & numerical data
- Abstract
Approximately 60 million persons in the United States live in rural counties, representing almost one fifth (19.3%) of the population.* In September 2020, COVID-19 incidence (cases per 100,000 population) in rural counties surpassed that in urban counties (1). Rural communities often have a higher proportion of residents who lack health insurance, live with comorbidities or disabilities, are aged ≥65 years, and have limited access to health care facilities with intensive care capabilities, which places these residents at increased risk for COVID-19-associated morbidity and mortality (2,3). To better understand COVID-19 vaccination disparities across the urban-rural continuum, CDC analyzed county-level vaccine administration data among adults aged ≥18 years who received their first dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine, or a single dose of the Janssen COVID-19 vaccine (Johnson & Johnson) during December 14, 2020-April 10, 2021 in 50 U.S. jurisdictions (49 states and the District of Columbia [DC]). Adult COVID-19 vaccination coverage was lower in rural counties (38.9%) than in urban counties (45.7%) overall and among adults aged 18-64 years (29.1% rural, 37.7% urban), those aged ≥65 years (67.6% rural, 76.1% urban), women (41.7% rural, 48.4% urban), and men (35.3% rural, 41.9% urban). Vaccination coverage varied among jurisdictions: 36 jurisdictions had higher coverage in urban counties, five had higher coverage in rural counties, and five had similar coverage (i.e., within 1%) in urban and rural counties; in four jurisdictions with no rural counties, the urban-rural comparison could not be assessed. A larger proportion of persons in the most rural counties (14.6%) traveled for vaccination to nonadjacent counties (i.e., farther from their county of residence) compared with persons in the most urban counties (10.3%). As availability of COVID-19 vaccines expands, public health practitioners should continue collaborating with health care providers, pharmacies, employers, faith leaders, and other community partners to identify and address barriers to COVID-19 vaccination in rural areas (2)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2021
- Full Text
- View/download PDF
17. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021.
- Author
-
Kriss JL, Reynolds LE, Wang A, Stokley S, Cole MM, Harris LQ, Shaw LK, Black CL, Singleton JA, Fitter DL, Rose DA, Ritchey MD, and Toblin RL
- Subjects
- Adolescent, Adult, Aged, COVID-19 epidemiology, Female, Health Services Accessibility, Humans, Male, Middle Aged, Time Factors, United States epidemiology, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Immunization Schedule, Vaccination Coverage statistics & numerical data
- Abstract
In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) received Emergency Use Authorization from the Food and Drug Administration.*
, † Both vaccines require 2 doses for a completed series. The recommended interval between doses is 21 days for Pfizer-BioNTech and 28 days for Moderna; however, up to 42 days between doses is permissible when a delay is unavoidable.§ Two analyses of COVID-19 vaccine administration data were conducted among persons who initiated the vaccination series during December 14, 2020-February 14, 2021, and whose doses were reported to CDC through February 20, 2021. The first analysis was conducted to determine whether persons who received a first dose and had sufficient time to receive the second dose (i.e., as of February 14, 2021, >25 days from receipt of Pfizer-BioNTech vaccine or >32 days from receipt of Moderna vaccine had elapsed) had received the second dose. A second analysis was conducted among persons who received a second COVID-19 dose by February 14, 2021, to determine whether the dose was received during the recommended dosing interval, which in this study was defined as 17-25 days (Pfizer-BioNTech) and 24-32 days (Moderna) after the first dose. Analyses were stratified by jurisdiction and by demographic characteristics. In the first analysis, among 12,496,258 persons who received the first vaccine dose and for whom sufficient time had elapsed to receive the second dose, 88.0% had completed the series, 8.6% had not received the second dose but remained within the allowable interval (≤42 days since the first dose), and 3.4% had missed the second dose (outside the allowable interval, >42 days since the first dose). The percentage of persons who missed the second dose varied by jurisdiction (range = 0.0%-9.1%) and among demographic groups was highest among non-Hispanic American Indian/Alaska Native (AI/AN) persons (5.1%) and persons aged 16-44 years (4.0%). In the second analysis, among 14,205,768 persons who received a second dose, 95.6% received the dose within the recommended interval, although percentages varied by jurisdiction (range = 79.0%-99.9%). Public health officials should identify and address possible barriers to completing the COVID-19 vaccination series to ensure equitable coverage across communities and maximum health benefits for recipients. Strategies to ensure series completion could include scheduling second-dose appointments at the first-dose administration and sending reminders for second-dose visits., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2021
- Full Text
- View/download PDF
18. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14, 2021.
- Author
-
Painter EM, Ussery EN, Patel A, Hughes MM, Zell ER, Moulia DL, Scharf LG, Lynch M, Ritchey MD, Toblin RL, Murthy BP, Harris LQ, Wasley A, Rose DA, Cohn A, and Messonnier NE
- Subjects
- Adolescent, Adult, Aged, COVID-19 epidemiology, Ethnicity statistics & numerical data, Female, Humans, Male, Middle Aged, Program Evaluation, Racial Groups statistics & numerical data, United States epidemiology, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Immunization Programs, Vaccination statistics & numerical data
- Abstract
In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) were authorized for emergency use in the United States for the prevention of coronavirus disease 2019 (COVID-19).* Because of limited initial vaccine supply, the Advisory Committee on Immunization Practices (ACIP) prioritized vaccination of health care personnel
† and residents and staff members of long-term care facilities (LTCF) during the first phase of the U.S. COVID-19 vaccination program (1). Both vaccines require 2 doses to complete the series. Data on vaccines administered during December 14, 2020-January 14, 2021, and reported to CDC by January 26, 2021, were analyzed to describe demographic characteristics, including sex, age, and race/ethnicity, of persons who received ≥1 dose of COVID-19 vaccine (i.e., initiated vaccination). During this period, 12,928,749 persons in the United States in 64 jurisdictions and five federal entities§ initiated COVID-19 vaccination. Data on sex were reported for 97.0%, age for 99.9%, and race/ethnicity for 51.9% of vaccine recipients. Among persons who received the first vaccine dose and had reported demographic data, 63.0% were women, 55.0% were aged ≥50 years, and 60.4% were non-Hispanic White (White). More complete reporting of race and ethnicity data at the provider and jurisdictional levels is critical to ensure rapid detection of and response to potential disparities in COVID-19 vaccination. As the U.S. COVID-19 vaccination program expands, public health officials should ensure that vaccine is administered efficiently and equitably within each successive vaccination priority category, especially among those at highest risk for infection and severe adverse health outcomes, many of whom are non-Hispanic Black (Black), non-Hispanic American Indian/Alaska Native (AI/AN), and Hispanic persons (2,3)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.